Healthy
Conditions
Keywords
Healthy, JNJ-61178104, Placebo, Safety
Brief summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity of JNJ-61178104 following a single ascending Intravenous (IV) dose administration and a single Subcutaneous (SC) dose administration in healthy participants.
Detailed description
This is a randomized, double-blind, placebo-controlled, single ascending dose, single site, interventional study. There will be 5 single ascending dose (SAD) IV cohorts and 1 SC cohort. Nine participants will be enrolled into each of 5 IV cohorts and 1 SC cohort and participants will be randomized at a ratio of 2:1 to receive JNJ-61178104 or placebo. The total duration of participants participation will be approximately 21 weeks including a Screening Visit up to 4 weeks prior to study drug administration. Participants will have an inpatient period consisting of 6 days/5 nights and will return to the study-site at Weeks 2, 3, 4, 5, 7, 9, 13, and 17. Participants will be evaluated for safety throughout the study.
Interventions
DRUGJNJ-61178104 Intravenous
Participants will receive JNJ-61178104 Intravenously on Day 1.
DRUGJNJ-61178104 Subcutaneous
Participants will receive JNJ-61178104 Subcutaneously on Day 1.
DRUGPlacebo
Participants will receive placebo on Day 1.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study * Participant must have a body weight in the range of 50 Kilogram (kg) to 100 kg, inclusive, and have a body mass index of 19 Kilogram per meter square (kg/m\^2) to 30 kg/m2, inclusive * Participant must be healthy on the basis of clinical laboratory tests performed at Screening and Day-1. If the results of the serum chemistry panel including liver enzymes, hematology panel, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's medical record with documented review confirmation by the investigator * Before randomization, a woman must not be of childbearing potential: a) Postmenopausal {greater than (\>) 45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level \>40 International Units Per Litre (IU/L) at Screening}; or b) Permanently sterilized (example, bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, oophorectomy); or c) Otherwise be incapable of pregnancy * Be considered eligible according to the following tuberculosis (TB) Screening criteria: a) Have no history of latent or active TB prior to Screening; b) Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination; c) Have had no recent close contact with a person with active TB; d) Have a negative T-Spot TB test result at Screening
Exclusion criteria
* Participant currently has or has a history of any clinically significant medical illness or medical disorders the investigator considers should exclude the participant, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, cardiac, vascular, metabolic, endocrine, rheumatologic, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease * Participant has a QT corrected according to Fridericia's formula (QTcF) interval \>450 msec, has a complete left or right bundle branch block, or has a history or current evidence of additional risk factors for torsades de pointes (example, heart failure, hypokalemia, family history of Long QT Syndrome) at Screening and at Day -1 * Participant has had major surgery, (example, requiring general anesthesia) within 4 months before Screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 17 weeks after the last dose of study drug administration * Participant plans to undergo non-major elective surgery within 4 weeks prior to study drug administration through the end of the study * Participant has a known or suspected intolerance or hypersensitivity to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or to any components of the formulation of JNJ-61178104 and its excipients used in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With Adverse Events Following Study Drug Administration as a Measure of Safety and Tolerability | Day 113 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| JNJ-61178104 Antibodies Concentration | Up to Day 113 | — |
| Cytokine Concentrations | Predose, Up to Day 113 | — |
| Maximum Observed Serum Concentration (Cmax) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration | Up to Day 113 | — |
| Area Under the Serum Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration | Up to Day 113 | — |
| Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration | Up to Day 113 | — |
| Serum Half-Life (t1/2) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration | Up to Day 113 | — |
| Serum Concentration of JNJ-61178104 | Up to Day 113 | — |
| Systemic Clearance (CL) Following Intravenous (IV) JNJ-61178104 Administration | Up to Day 113 | — |
| Apparent Clearance (CL/F) Following Subcutaneous (SC) JNJ-61178104 Administration | Up to Day 113 | — |
| Volume of Distribution (Vz) Following Intravenous (IV) JNJ-61178104 Administration | Up to Day 113 | — |
| Apparent Volume of Distribution (Vz/F) Following Subcutaneous (SC) JNJ-61178104 Administration | Up to Day 113 | — |
| Absolute Bioavailability (F[abs]) Following Subcutaneous (SC) JNJ-61178104 Administration | Up to Day 113 | The F is the percentage of the subcutaneously administered dose that is systemically available relative to an intravenous (IV) administration. It is calculated as (AUC \[0-infinity\] for 1 mg/kg SC JNJ-61178104)/(AUC \[0-infinity\] for 1 mg/kg IV JNJ-61178104 )\*100, where the AUC (0-infinity) is area under the concentration-time curve from time zero to extrapolated infinite time. |
| Time to Reach Maximum Observed Serum Concentration (Tmax) Following Subcutaneous (SC) JNJ-61178104 Administration | Up to Day 113 | — |
Countries
Belgium
Outcome results
None listed